Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication.

Podobne knjige/članki

• Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication.
  od: Kleim, J P, et al.
  Izdano: (1993)
• Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile and Val-75-->Leu or Ile) HIV-1 mutants.
  od: Kleim, J P, et al.
  Izdano: (1996)
• Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720.
  od: Balzarini, J, et al.
  Izdano: (1994)
• Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication.
  od: Romero, D L, et al.
  Izdano: (1991)
• Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase.
  od: Boyer, P L, et al.
  Izdano: (1993)